The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer

Nucleic Acids Research

Volumn 44, Issue 3, 2016, Pages 1227-1246

  Hopkins, Thomas G ^a   Mura, Manuela ^a   Al Ashtal, Hiba A ^b   Lahr, Roni M ^b   Abd Latip, Normala ^a   Sweeney, Katrina ^a   Lu, Haonan ^a   Weir, Justin ^c   El Bahrawy, Mona ^c   Steel, Jennifer H ^a   Ghaem Maghami, Sadaf ^a   Aboagye, Eric O ^a   Berman, Andrea J ^b   Blagden, Sarah P ^a,d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; PACLITAXEL; PROTEIN BCL 2; RNA BINDING PROTEIN; RNA BINDING PROTEIN LARP1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; AUTOANTIGEN; IL2RG PROTEIN, MOUSE; INTERLEUKIN 2 RECEPTOR GAMMA; PROTEIN BINDING; RIBONUCLEOPROTEIN; SS-B ANTIGEN;

3' UNTRANSLATED REGION; ANALYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BCL2 GENE; BIK GENE; BINDING AFFINITY; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CARCINOGENICITY; CELL DEATH; CELL POPULATION; CELL VIABILITY; CLONOGENESIS; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; GENE INTERACTION; GENETIC ASSOCIATION; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; MULTICENTER STUDY (TOPIC); NONHUMAN; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN RNA BINDING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RNA STABILITY; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSCRIPTOMIC ANALYSIS; ANIMAL; CELL SURVIVAL; CONFOCAL MICROSCOPY; DEFICIENCY; DISEASE COURSE; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HELA CELL LINE; KNOCKOUT MOUSE; METABOLISM; NONOBESE DIABETIC MOUSE; OVARY TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SCID MOUSE; SURVIVAL ANALYSIS; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTOANTIGENS; BLOTTING, WESTERN; CARCINOGENESIS; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MICROSCOPY, CONFOCAL; OVARIAN NEOPLASMS; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEOPROTEINS; RNA INTERFERENCE; SURVIVAL ANALYSIS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84965060086     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkv1515     Document Type: Article

References (61)

1. Wurth, L. (2012) Versatility of RNA-binding proteins in cancer. Comp. Funct. Genomics, 2012, 178525.
2. Schwanhausser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W. and Selbach, M. (2013) Corrigendum: global quantification of mammalian gene expression control. Nature, 495, 126-127.
3. Sharova, L.V., Sharov, A.A., Nedorezov, T., Piao, Y., Shaik, N. and Ko, M.S. (2009) Database for mRNA half-life of 19 977 genes obtained by DNA microarray analysis of pluripotent and differentiating mouse embryonic stem cells. DNA Res., 16, 45-58.
4. Morey, J.S. and Van Dolah, F.M. (2013) Global analysis of mRNA half-lives and de novo transcription in a dinoflagellate, Karenia brevis. PLoS One, 8, e66347.
5. Anderson, P., Phillips, K., Stoecklin, G. and Kedersha, N. (2004) Post-transcriptional regulation of proinflammatory proteins. J.Leukoc. Biol., 76, 42-47.
6. Lazaris-Karatzas, A. and Sonenberg, N. (1992) The mRNA 5 cap-binding protein, eIF-4E, cooperates with v-myc or E1A in the transformation of primary rodent fibroblasts. Mol. Cell. Biol., 12, 1234-1238.
7. Bousquet-Antonelli, C. and Deragon, J.M. (2009) A comprehensive analysis of the La-motif protein superfamily. RNA, 15, 750-764.
8. Trotta, R., Vignudelli, T., Candini, O., Intine, R.V., Pecorari, L., Guerzoni, C., Santilli, G., Byrom, M.W., Goldoni, S., Ford, L.P. et al. (2003) BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell, 3, 145-160.
9. Sommer, G., Dittmann, J., Kuehnert, J., Reumann, K., Schwartz, P.E., Will, H., Coulter, B.L., Smith, M.T. and Heise, T. (2011) The RNA-binding protein La contributes to cell proliferation and CCND1 expression. Oncogene, 30, 434-444.
10. Sommer, G., Rossa, C., Chi, A.C., Neville, B.W. and Heise, T. (2011) Implication of RNA-binding protein La in proliferation, migration and invasion of lymph node-metastasized hypopharyngeal SCC cells. PLoS One, 6, e25402.
11. Stavraka, C. and Blagden, S. (2015) The la-related proteins, a family with connections to cancer. Biomolecules, 5, 2701-2722.
12. Lahr, R., Mack, S., Héroux, A., Blagden, S., Bousquet-Antonelli, C., Deragon, J. and Berman, A. (2015) The La-related protein 1-specific domain repurposes HEAT-like repeats to directly bind a TOP sequence. Nucleic Acids Res., 43, 8077-8088.
13. Aoki, K., Adachi, S., Homoto, M., Kusano, H., Koike, K. and Natsume, T. (2013) LARP1 specifically recognizes the 3 terminus of poly(A) mRNA. FEBS Lett., 587, 2173-2178.
14. Merret, R., Descombin, J., Juan, Y.T., Favory, J.J., Carpentier, M.C., Chaparro, C., Charng, Y.Y., Deragon, J.M. and Bousquet-Antonelli, C. (2013) XRN4 and LARP1 are required for a heat-triggered mRNA decay pathway involved in plant acclimation and survival during thermal stress. Cell Rep., 5, 1279-1293.
15. Mura, M., Hopkins, T.G., Michael, T., Abd-Latip, N., Weir, J., Aboagye, E.O., Mauri, F., Jameson, C., Sturge, J., Gabra, H. et al. (2015) LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression. Oncogene, 34, 5025-5036.
16. Tcherkezian, J., Cargnello, M., Romeo, Y., Huttlin, E.L., Lavoie, G., Gygi, S.P. and Roux, P.P. (2014) Proteomic analysis of cap-dependent translation identifies LARP1 as a key regulator of 5- TOP mRNA translation. Genes Dev., 28, 357-371.
17. Fonseca, B.D., Zakaria, C., Jia, J.J., Graber, T.E., Svitkin, Y., Tahmasebi, S., Healy, D., Hoang, H.D., Jensen, J.M., Diao, I.T. et al. (2015) La-related protein 1 (LARP1) represses terminal oligopyrimidine (TOP) mRNA translation downstream of mTOR complex 1 (mTORC1). J. Biol. Chem. 290, 15996-16020.
18. Xie, C., Huang, L., Xie, S., Xie, D., Zhang, G., Wang, P., Peng, L. and Gao, Z. (2013) LARP1 predict the prognosis for early-stage and AFP-normal hepatocellular carcinoma. J. Transl. Med., 11, 272-276.
19. Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. and Forman, D. (2011) Global cancer statistics. CA Cancer J. Clin., 61, 69-90.
20. Agarwal, R. and Kaye, S.B. (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer, 3, 502-516.
21. Siegel, R., Naishadham, D. and Jemal, A. (2013) Cancer statistics, 2013. CA Cancer J. Clin., 63, 11-30.
22. Flesken-Nikitin, A., Hwang, C.I., Cheng, C.Y., Michurina, T.V., Enikolopov, G. and Nikitin, A.Y. (2013) Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature, 495, 241-245.
23. Yasuda, K., Torigoe, T., Morita, R., Kuroda, T., Takahashi, A., Matsuzaki, J., Kochin, V., Asanuma, H., Hasegawa, T., Saito, T. et al. (2013) Ovarian cancer stem cells are enriched in side population and aldehyde dehydrogenase bright overlapping population. PLoS One, 8, e68187.
24. Li, R., Yu, C., Li, Y., Lam, T.W., Yiu, S.M., Kristiansen, K. and Wang, J. (2009) SOAP2: An improved ultrafast tool for short read alignment. Bioinformatics, 25, 1966-1967.
25. Mortazavi, A., Williams, B.A., McCue, K., Schaeffer, L. and Wold, B. (2008) Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods, 5, 621-628.
26. Keene, J.D., Komisarow, J.M. and Friedersdorf, M.B. (2006) RIP-Chip: The isolation and identification of mRNAs, microRNAs and protein components of ribonucleoprotein complexes from cell extracts. Nat. Protoc., 1, 302-307.
27. Burrows, C., Abd Latip, N., Lam, S.J., Carpenter, L., Sawicka, K., Tzolovsky, G., Gabra, H., Bushell, M., Glover, D.M., Willis, A.E. et al. (2010) The RNA binding protein Larp1 regulates cell division, apoptosis and cell migration. Nucleic Acids Res., 38, 5542-5553.
28. Kent, W.J., Sugnet, C.W., Furey, T.S., Roskin, K.M., Pringle, T.H., Zahler, A.M. and Haussler, D. (2002) The human genome browser at UCSC. Genome Res., 12, 996-1006.
29. Ishimaru, D., Zuraw, L., Ramalingam, S., Sengupta, T.K., Bandyopadhyay, S., Reuben, A., Fernandes, D.J. and Spicer, E.K. (2010) Mechanism of regulation of bcl-2 mRNA by nucleolin and A+U-rich element-binding factor 1 (AUF1). J. Biol. Chem., 285, 27182-27191.
30. Workman, P., Aboagye, E.O., Balkwill, F., Balmain, A., Bruder, G., Chaplin, D.J., Double, J.A., Everitt, J., Farningham, D.A., Glennie, M.J. et al. (2010) Guidelines for the welfare and use of animals in cancer research. Br. J. Cancer, 102, 1555-1577.
31. Heckman, C.A., Mehew, J.W., Ying, G.G., Introna, M., Golay, J. and Boxer, L.M. (2000) A-Myb up-regulates Bcl-2 through a Cdx binding site in t(14;18) lymphoma cells. J. Biol. Chem., 275, 6499-6508.
32. Cancer Genome Atlas Research Network. (2011) Integrated genomic analyses of ovarian carcinoma. Nature, 474, 609-615.
33. Hendrix, N.D., Wu, R., Kuick, R., Schwartz, D.R., Fearon, E.R. and Cho, K.R. (2006) Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res., 66, 1354-1362.
34. Bonome, T., Levine, D.A., Shih, J., Randonovich, M., Pise-Masison, C.A., Bogomolniy, F., Ozbun, L., Brady, J., Barrett, J.C., Boyd, J. et al. (2008) A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res., 68, 5478-5486.
35. Gyorffy, B., Lanczky, A., Eklund, A.C., Denkert, C., Budczies, J., Li, Q. and Szallasi, Z. (2010) An online survival analysis tool to rapidly assess the effect of 22, 277 genes on breast cancer prognosis using microarray data of 1, 809 patients. Breast Cancer Res. Treat, 123, 725-731.
36. Gyorffy, B., Lanczky, A. and Szallasi, Z. (2012) Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr. Relat. Cancer, 19, 197-208.
37. Reinhold, W.C., Sunshine, M., Liu, H., Varma, S., Kohn, K.W., Morris, J., Doroshow, J. and Pommier, Y. (2012) CellMiner: A web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res., 72, 3499-3511.
38. Ardehali, R., Inlay, M.A., Ali, S.R., Tang, C., Drukker, M. and Weissman, I.L. (2011) Overexpression of BCL2 enhances survival of human embryonic stem cells during stress and obviates the requirement for serum factors. Proc. Natl. Acad. Sci. U.S.A., 108, 3282-3287.
39. Wang, J., Zhou, J.Y., Zhang, L. and Wu, G.S. (2009) Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells. Cell Cycle, 8, 3191-3198.
40. Lagadinou, E.D., Sach, A., Callahan, K., Rossi, R.M., Neering, S.J., Minhajuddin, M., Ashton, J.M., Pei, S., Grose, V., O'Dwyer, K.M. et al. (2013) BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell, 12, 329-341.
41. Mano, Y., Kikuchi, Y., Yamamoto, K., Kita, T., Hirata, J., Tode, T., Ishii, K. and Nagata, I. (1999) Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. Eur. J. Cancer, 35, 1214-1219.
42. Mignone, F., Gissi, C., Liuni, S. and Pesole, G. (2002) Untranslated regions of mRNAs. Genome Biol., 3, Reviews 0004.1-Reviews 0004.10.
43. Nykamp, K., Lee, M.H. and Kimble, J. (2008) C. elegans La-related protein, LARP-1, localizes to germline P bodies and attenuates Ras-MAPK signaling during oogenesis. RNA, 14, 1378-1389.
44. Hou, J.Y., Rodriguez-Gabin, A., Samaweera, L., Hazan, R., Goldberg, G.L., Horwitz, S.B. and McDaid, H.M. (2013) Exploiting MEK inhibitor-mediated activation of ERalpha for therapeutic intervention in ER-positive ovarian carcinoma. PLoS One, 8, e54103.
45. Stronach, E.A., Alfraidi, A., Rama, N., Datler, C., Studd, J.B., Agarwal, R., Guney, T.G., Gourley, C., Hennessy, B.T., Mills, G.B. et al. (2011) HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res., 71, 4412-4422.
46. Magee, J.A., Piskounova, E. and Morrison, S.J. (2012) Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell, 21, 283-296.
47. Kryczek, I., Liu, S., Roh, M., Vatan, L., Szeliga, W., Wei, S., Banerjee, M., Mao, Y., Kotarski, J., Wicha, M.S. et al. (2012 Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int. J. Cancer, 130, 29-39.
48. Gupta, P.B., Onder, T.T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R.A. and Lander, E.S. (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell, 138, 645-659.
49. Bareiss, P.M., Paczulla, A., Wang, H., Schairer, R., Wiehr, S., Kohlhofer, U., Rothfuss, O.C., Fischer, A., Perner, S., Staebler, A. et al. (2013) SOX2 expression associates with stem cell state in human ovarian carcinoma. Cancer Res., 73, 5544-5555.
50. Bast, R.C. Jr, Hennessy, B. and Mills, G.B. (2009) The biology of ovarian cancer: new opportunities for translation. Nat. Rev. Cancer, 9, 415-428.
51. Bowen, N.J., Walker, L.D., Matyunina, L.V., Logani, S., Totten, K.A., Benigno, B.B. and McDonald, J.F. (2009) Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells. BMC Med. Genomics, 2, 71.
52. Tone, A.A., Begley, H., Sharma, M., Murphy, J., Rosen, B., Brown, T.J. and Shaw, P.A. (2008) Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clin. Cancer Res., 14, 4067-4078.
53. Banerjee, S., Rustin, G., Paul, J., Williams, C., Pledge, S., Gabra, H., Skailes, G., Lamont, A., Hindley, A., Goss, G. et al. (2013) A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: An SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Ann. Oncol., 24, 679-687.
54. Yang, R., Gaidamakov, S.A., Xie, J., Lee, J., Martino, L., Kozlov, G., Crawford, A.K., Russo, A.N., Conte, M.R., Gehring, K. et al. (2011) La-related protein 4 binds poly(A), interacts with the poly(A)-binding protein MLLE domain via a variant PAM2w motif, and can promote mRNA stability. Mol. Cell. Biol., 31, 542-556.
55. Jiang, M. and Milner, J. (2003) Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. Genes Dev., 17, 832-837.
56. Kupryjanczyk, J., Szymanska, T., Madry, R., Timorek, A., Stelmachow, J., Karpinska, G., Rembiszewska, A., Ziolkowska, I., Kraszewska, E., Debniak, J. et al. (2003) Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. Br. J. Cancer, 88, 848-854.
57. Liu, Q., Nguyen, D.H., Dong, Q., Shitaku, P., Chung, K., Liu, O.Y., Tso, J.L., Liu, J.Y., Konkankit, V., Cloughesy, T.F. et al. (2009) Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J. Neurooncol., 94, 1-19.
58. Kwon, S.C., Yi, H., Eichelbaum, K., Fohr, S., Fischer, B., You, K.T., Castello, A., Krijgsveld, J., Hentze, M.W. and Kim, V.N. (2013) The RNA-binding protein repertoire of embryonic stem cells. Nat. Struct. Mol. Biol., 20, 1122-1130.
59. Kurosu, T., Ohga, N., Hida, Y., Maishi, N., Akiyama, K., Kakuguchi, W., Kuroshima, T., Kondo, M., Akino, T., Totsuka, Y. et al. (2011) HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium. Br. J. Cancer, 104, 819-829.
60. Chang, N., Yi, J., Guo, G., Liu, X., Shang, Y., Tong, T., Cui, Q., Zhan, M., Gorospe, M. and Wang, W. (2010) HuR uses AUF1 as a cofactor to promote p16INK4 mRNA decay. Mol. Cell. Biol., 30, 3875-3886.
61. Blanco, F.F., Jimbo, M., Wulfkuhle, J., Gallagher, I., Deng, J., Enyenihi, L., Meisner-Kober, N., Londin, E., Rigoutsos, I., Sawicki, J.A. et al. (2015) The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells. Oncogene, (doi:10.1038/onc.2015.325; Sept 21, epub ahead of print).